Related references
Note: Only part of the references are listed.A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
J. C. Soria et al.
ANNALS OF ONCOLOGY (2016)
Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma
Mayura Meerang et al.
MOLECULAR ONCOLOGY (2016)
Antitumor effect of Trametinib, a selective MEK inhibitor, in combination with 4-methylumbelliferone, a hyaluronic acid synthesis inhibitor, in Malignant pleural mesothelioma cell lines
Hiroyuki Cho et al.
CANCER RESEARCH (2015)
Overexpression of activin-A and -B in malignant mesothelioma - Attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth
Jenni A. Tamminen et al.
EXPERIMENTAL CELL RESEARCH (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer
K. R. Auger et al.
EUROPEAN JOURNAL OF CANCER (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Phosphorylation of Focal Adhesion Kinase at Tyr397 in Gastric Carcinomas and its Clinical Significance
I-Rue Lai et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK
P. I. Poulikakos et al.
ONCOGENE (2006)
Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma
Merivane de Melo et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2006)
The role of focal-adhesion kinase in cancer. A ew therapeutic opportunity
GW McLean et al.
NATURE REVIEWS CANCER (2005)
Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells
L Vintman et al.
CANCER (2005)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
MJ Byrne et al.
ANNALS OF ONCOLOGY (2004)
Biological significance of focal adhesion kinase in ovarian cancer - Role in migration and invasion
AK Sood et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis
C Recher et al.
CANCER RESEARCH (2004)
Share Paper
